RoboSense Wins CES 2020 Innovation Award for Autonomous Vehicle Technology
8.11.2019 12:19:00 EET | Business Wire | Press release
RoboSense http://www.robosense.ai, the world’s leading autonomous driving LiDAR perception solution provider, announced today that it has won the CES 2020 Innovation Award the second year in a row for autonomous vehicle technology. RoboSense won this year’s CES 2020 Innovation Award for the first MEMS-based Smart LiDAR Sensor, the RoboSense RS-LiDAR-M1, winning in the Vehicle Intelligence and Self-Driving Technology category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191108005194/en/
RoboSense RS-LiDAR-M1 (Graphic: Business Wire)
The RoboSense award-winning RS-LiDAR-M1 is the world’s first and only MEMS-based smart LiDAR sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC(System on a Chip). The RS-LiDAR-M1 goes beyond traditional LiDAR, providing full data collection and comprehension. As a ground-breaking product, the RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but also processes road data in real-time, with a built-in AI algorithm and SoC, while at the same time synchronizing high-precision positioning output; road traffic signage; lane markings, driving areas, road curbs, and obstacle detection; tracking; and classification. Also, it is the world’s smallest MEMS-based solid-state LiDAR, providing a low cost, high stability, and superior manufacturability to meet automotive-grade and serial production requirements.
“Driving Safety is the most critical challenge for the Autonomous driving vehicles. Perception is the first sense for the AD vehicles to precept the surrounding environment. To ensure a completely safe perception working in all conditions, LiDAR with smart perception algorithm and supporting functions are indispensable. We are very proud that our smart LiDR sensor concept have been recognized by the customers and different application users, ” said Dr. Leilei Shinohara, RoboSense Vice President of R&D.
The RoboSenseRS-LiDAR-M1 Smart LiDAR Sensor will be on display in the Innovation Awards Showcaseat the upcoming CES 2020. The complete list of CES 2020 Innovation Honorees, including product descriptions and photos, can be found at CES.tech/Innovation. RoboSense will be exhibiting at booth 6138, LVCC North Hall, CES 2020 from Jan. 7 – 10, 2020, and tabletop No. 602 at CES Unveiled Las Vegas, on Jan. 5, 2020, 5 – 8:30 p.m. PST.
About CES & CES Innovation Awards
An annual program that celebrates outstanding design, the CES Innovation Awards recognizes the best technology products of the year. The CES Innovation Awards are sponsored by the Consumer Technology Association (CTA)™, owner and producer of CES, the world’s largest and most influential technology event.
CES 2020 will showcase life-changing technology across every major industry. CES provides access to the very latest transformative tech, such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports tech, machine learning and more. For the latest news and show announcements, visit CES.tech. Follow CES online at CES.tech and on social.
About RoboSense
Founded in 2014, RoboSense is the world’s leading provider of LiDAR environment perception solutions designed to provide a higher performance, safer, more reliable, and lower cost LiDAR system for autonomous vehicles. RoboSense has entered into strategic partnerships with many top car companies, tier one manufacturers and technology companies with a global reach. For more information about RoboSense, visit: https://www.robosense.ai
Photos:
CES 2020 Innovation Award Honoree Logo: http://www.thomas-pr.com/136/photos/robosenseces2020innovationawardlogo.html
RS-LiDAR-M1 Smart LiDAR Sensor: http://www.thomas-pr.com/136/photos/robosensem1lidar.html
RoboSense Logo: http://www.thomas-pr.com/136/photos/robosenselogo.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005194/en/
Contact information
Press:
Karen Thomas/Eva Yutani
Emails: kthomas@thomaspr.com / eyutani@thomaspr.com
(631) 549-7575 website: http://www.thomaspr.com
Company:
Cassie Gong, Overseas PR Manager
Email: sqgong@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom